Pyro Pharmaceuticals Elects New Board Member

Fero Industries, Inc. Pyro Pharmaceuticals, Inc., announced that Philip N. Sussman has recently been appointed to the board of directors.

Sussman is Managing Partner of The Channel Group and has served as a member of senior management (Head of Business Development, CFO, and CEO) of several public and private biotechnology companies. Sussman has a B.S. in Physics from the State University of New York at Stony Brook, Master of Science in Biotechnology from Manhattan College, and an S.M. in Management with a concentration in Finance from the Sloan School of Management, MIT.

"Phil provides a needed component to our board with his expertise in licensing, business development, and corporate governance. He complements our other board members, Carol L. Epstein, M.D., and Ving J. Lee, Ph.D.," said Alan M. Schechter, Pyro's Chairman and CEO.

Dr. Epstein has over 25 years of experience in clinical drug development and trials, regulatory affairs, toxicology, and drug licensing. She has worked for both biotechnology companies and big pharma. Dr. Epstein has a B.S. from the Massachusetts Institute of Technology and received her M.D. from Yale University School of Medicine. She is board certified in Rheumatology and Internal Medicine. Dr. Lee is a highly regarded medicinal chemist with expertise in infectious disease. Dr. Lee spent 16 years in the infectious disease group at Lederle Laboratories, the last 4 years as Head of the Infectious Disease Chemistry department. Currently, Dr. Lee is the Chief Executive Officer and Chief Scientific Officer for Adesis Inc., a private chemistry contract research organization (New Castle, DE) and Chief Scientific Officer and Co-founder of Limerick BioPharma (South San Francisco). Dr. Lee holds sixty issued patents on various antibiotic compounds and anti-bacterial genes. Dr. Lee received his B.A. in chemistry from Ohio State University and his M.S., and Ph.D. degrees in chemistry from the University of Illinois-Urbana. He was also an NIH post-grad fellow at the University of Illinois-Urbana and Harvard University. Schechter also said, "with the addition of Sussman, we have a qualified board in place to guide us through the merger with Fero Industries (Calgary, Alberta) and set the strategic and operational direction of Pyro Pharmaceuticals to achieve its mission of developing a new class of antibiotics."

((Comments on this story may be sent to health@closeupmedia.com))

Related terms: alberta, biotechnology, business, calgary, ceo, clinical, college, contract, corporate, disease, executive, finance, health, illinois, medicine, new york, ohio, pharmaceuticals, physics, research, science, technology, university